Crescent Biopharma vs CytomX Therapeutics
CBIO and CTMX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and CTMX compare
Crescent Biopharma is the larger company, worth 1.2 times as much as CytomX Therapeutics ($534M against $445M).
CytomX Therapeutics keeps more of each dollar of sales as profit, with a net margin of −609% compared with −728% at Crescent Biopharma.
Crescent Biopharma scores higher on the StockData Score (10 against 8 for CytomX Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | CTMX |
|---|---|---|
| Size and price | ||
| Market cap | $534M | $445M |
| Share price | $14.37 | $2.04 |
| Change, 1 year | 8.5% | −50.2% |
| Change, 5 years | −92.4% | −72.2% |
| Beta (5Y) | 1.63 | 1.58 |
| Employees | 44 | 69 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 35.6× | 31.7× (better) |
| P/B | 1.9× | 1.6× (better) |
| FCF yield | −15.4% | −11.5% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −87.7% |
| Revenue growth, 5Y average | 1.3% | 2.2% (better) |
| Net income growth (TTM) | – | −405% |
| EPS growth (TTM) | – | −215% |
| Profitability | ||
| Operating margin | −1217% | −676% (better) |
| Net margin | −728% | −609% (better) |
| FCF margin | −550% | −364% (better) |
| Return on equity | −55.8% | −43.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.57 (better) | 7.82 |
| Altman Z-score | 10.62 (better) | 0.58 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −55.0% |
| Shareholder yield | 0.00% (better) | −55.0% |
| Ownership | ||
| Held by institutions | 79.7% | 97.9% |
| Held by insiders | 38.6% | 1.5% |
| Insider net buying, 12 months | $29.1M (better) | −$1.2M |
| Short interest, % of float | 18.3% | 21.1% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.